Catarina Brito,
Research Associate
Catarina Brito graduated in Biochemistry at the Faculdade de Ciências da Universidade
de Lisboa, and holds a PhD in Biochemistry & Cell Biology from Instituto de Tecnologia
Quimica Biológica da Universidade Nova de Lisboa (ITQB-UNL).
After 7 years of research in the areas of glycobiology and intracellular trafficking in
human cells, in 2007 Catarina joined the Animal Cell Technology Unit (ACTU) of iBET
and ITQB-UNL as a Post-Doc to work on Stem Cell Bioprocessing. Her work contributed
for the establishment of novel bioreactor-based strategies for scalable expansion,
differentiation and cryopreservation, with a strong focus on quantitative
characterization of SC and population dynamics.
Catarina is a senior Research Associate of the ACTU since 2009 (http://tca.itqb.unl.pt),
and her current research, with funding from Fundação para a Ciência e Tecnologia
(FCT, Portugal), the Innovative Medicines Initiative Joint Undertaking (IMI - EU &
EFPIA) and Pharmaceutical industry, focus on integration of bioprocessing
development and molecular cell biology techniques to deliver novel and validated 3D
in vitro models for preclinical research, using stem cells and patient-derived cells.
Currently, her research targets are Cancer (solid tumors), Central Nervous System
diseases, neuronal toxicology and hepatic toxicology.
Quimica Biológica da Universidade Nova de Lisboa (ITQB-UNL).
After 7 years of research in the areas of glycobiology and intracellular trafficking in
human cells, in 2007 Catarina joined the Animal Cell Technology Unit (ACTU) of iBET
and ITQB-UNL as a Post-Doc to work on Stem Cell Bioprocessing. Her work contributed
for the establishment of novel bioreactor-based strategies for scalable expansion,
differentiation and cryopreservation, with a strong focus on quantitative
characterization of SC and population dynamics.
Catarina is a senior Research Associate of the ACTU since 2009 (http://tca.itqb.unl.pt),
and her current research, with funding from Fundação para a Ciência e Tecnologia
(FCT, Portugal), the Innovative Medicines Initiative Joint Undertaking (IMI - EU &
EFPIA) and Pharmaceutical industry, focus on integration of bioprocessing
development and molecular cell biology techniques to deliver novel and validated 3D
in vitro models for preclinical research, using stem cells and patient-derived cells.
Currently, her research targets are Cancer (solid tumors), Central Nervous System
diseases, neuronal toxicology and hepatic toxicology.
|
|
